Artec receives Eurostars grant to assess AAA rupture risk
Artec Diagnosis today announces that the company’s application for a Eurostars grant comprising the development of a rupture risk assessment tool for Abdominal Aortic Aneurysms has been approved. Artec Diagnosis is the coordinator of the project. Other partners include Karolinska Institute and University Hospital, KTH Royal Institute of Technology and Universitaetsklinikum Augsburg.
The grant commences provides additional resources for the Company's development of a patient individual treatment of Abdominal Aortic Aneurysm (AAA) patients. Artec Diagnosis, together with the other partners in the consortium, will develop a software platform that performs a reliable AAA rupture risk assessment using regularly taken CT images together with patient parameters, such as age, gender and medication history. The combination of Artificial Intelligence and vascular biomechanics simulation is greatly superior to any other AAA risk assessment approach. In-house data showed 80% accuracy at 100% specificity in a retrospective patient cohort.
CEO Carmen Gasser comments: "We are delighted to have received the announcement that our application has been granted and we can now, with greater focus, develop our AAA rupture risk assessment into a first-in-class treatment that can benefit patients. The partners in the consortium are all reputable and leading in their respective research fields, and we look forward to collaborating in this project."
For further information, please contact:
Artec Diagnosis AB
Stockholmsvaegen 51
18274 Stocksund, Sweden
carmen.gasser@artecdiagnosis.com
About Abdominal Aortic Aneurysms. An abdominal aortic aneurysm is a bulge or swelling in the aorta, the main blood vessel that runs from the heart down through the chest and tummy. The formation can be dangerous if it is not spotted early on. It can get bigger over time and could burst (rupture), causing life-threatening bleeding. The number of patients with Abdominal Aortic Aneurysms is rapidly increasing globally. It is a common aortic disease and its prevalence increases strongly with age. The only treatment to prevent aneurysms from rupture is aneurysm repair, a fully surgical and minimal-invasive intervention. There is thus an already large and growing global need for new treatment parameters. An optimal health care treatment of patients critically depends on a reliable rupture risk assessment.
About Artec Diagnosis AB. Artec Diagnosis is a biotech company focused on the treating of aneurysm patients. The primary focus is in software development, biomechanical computer simulations, clinical data management and visualization. The company was founded in 2018, and is based in Stockholm, Sweden.
About Karolinska Institute and University Hospital. Karolinska Institute and University Hospital is one of the world’s leading Medical universities and stands for more than 40% of all Academic Medical Research in Sweden. Since 1901 the Nobel Assembly at Karolinska Institute has selected the Nobel laureates in Physiology or Medicine.
About KTH Royal Institute of Technology. KTH Royal Institute of Technology is responsible for 1/3 of Sweden’s capacity for engineering studies and technical research at post-secondary level. KTH has 1,600 active postgraduate students, 4,300 staff and conducts top-notch education and research of a broad spectrum - from natural science to all branches of technology, incl. architecture, industrial economics, urban planning, work science and environ-mental technology. A large number of national Centres of Excellence are located at KTH.
(c) 2021 ARTEC DIAGNOSIS AB. ALL RIGHTS RESERVED.